Central Nervous System Lymphoma Clinical Trial
Official title:
LCCC1841: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma. Currently, there are no FDA-approved treatments for relapsed CNS lymphoma. Although acalabrutinib has not been approved for the treatment of CNS lymphoma, it was approved for the treatment of another type of lymphoma (mantle cell), by the Food and Drug Administration (FDA). Acalabrutinib acts similar to another cancer drug called ibrutinib. lbrutinib was tested in several research trials for the management of CNS lymphomas, and the results were promising. Acalabrutinib and ibrutinib attack a similar target found in CNS lymphoma. Acalabrutinib may do a better job in attacking this target than ibrutinib. The study doctors will be looking to see if acalabrutinib can shrink cancer cells. The participants will be given acalabrutinib and isavuconazole, because isavuconazole helps in preventing fungal infections that may occur during acalabrutinib treatment.
This multicenter open-label, single-arm, pilot study explores a safe and effective treatment for relapsed central nervous system lymphoma. The study investigates the antitumor effects and safety of acalabrutinib in subjects with relapsed primary central nervous system lymphoma (PCNSL) or relapsed secondary CNS lymphoma (SCNSL) with no evidence of current systemic disease. Types of SCNSL included in the study are: Diffuse large B-cell lymphoma, mantle cell lymphoma, plasmablastic lymphoma, and lymphoplasmacytic lymphoma. Up to 16 subjects will be enrolled to attain a total of 15 evaluable subjects. Duration of Therapy: Treatment with acalabrutinib and isavuconazole will continue unless - Disease progression - Inter-current illness that prevents further administration of treatment - Unacceptable adverse event(s) - Pregnancy - Subject decides to withdraw from study treatment, - General or specific changes in the subject's condition render the subject unacceptable for further treatment in the judgment of the investigator, or - Subject is lost to follow up Duration of Follow-up All subjects will be followed for survival for 5 years or until death, whichever occurs first. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04516655 -
A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients
|
Phase 2 | |
| Recruiting |
NCT05054426 -
Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL
|
Phase 3 | |
| Recruiting |
NCT02623010 -
Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT00293475 -
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03342586 -
Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
|
||
| Terminated |
NCT02420795 -
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05625594 -
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma
|
Phase 1 | |
| Completed |
NCT01011920 -
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
|
Phase 2 | |
| Completed |
NCT00967200 -
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
|
N/A | |
| Recruiting |
NCT03684980 -
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
|
Early Phase 1 | |
| Recruiting |
NCT04938297 -
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
|
Phase 2 | |
| Completed |
NCT01458730 -
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
|
Phase 2 | |
| Completed |
NCT00153530 -
Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)
|
Phase 4 | |
| Recruiting |
NCT05816746 -
Decitabine and Anti-PD-1 in R/R DLBCL
|
Phase 2 | |
| Active, not recruiting |
NCT03962127 -
MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
|
||
| Completed |
NCT03690895 -
Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
|
||
| Recruiting |
NCT05114330 -
Secondary Central Nervous System Lymphoma Registry - Charité
|
||
| Completed |
NCT00103038 -
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
|
N/A | |
| Recruiting |
NCT03964090 -
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
|
Phase 2 | |
| Recruiting |
NCT02952508 -
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
|
Phase 2 |